Latest Period
Q4 2025
Security Snapshot
Fulcrum Therapeutics, Inc. - Common Stock (FULC) Institutional Ownership
CUSIP: 359616109
13F Institutional Holders and Ownership History from Q3 2019 to Q1 2026
Institutions Reporting
172
Shares (Excl. Options)
67,444,422
Price
$11.31
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- FULC on Nasdaq
- Shares outstanding
- 67,171,444
- Price per share
- $7.67
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 67,444,422
- Total reported value
- $762,744,178
- % of total 13F portfolios
- 0%
- Share change
- +11,821,898
- Value change
- +$134,984,797
- Number of holders
- 172
- Price from insider filings
- $7.67
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- FULC - Fulcrum Therapeutics, Inc. - Common Stock is tracked under CUSIP 359616109.
- 172 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 172 to 77 between Q4 2025 and Q1 2026.
- Reported value moved from $762,744,178 to $136,118,842.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 172 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 359616109?
CUSIP 359616109 identifies FULC - Fulcrum Therapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 359616109:
Significant Owners of Fulcrum Therapeutics, Inc. - Common Stock (FULC) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | -12% | $67,231,227 | +$6,025,691 | 6,649,973 | +9.8% | RA Capital Management, L.P. | 31 Dec 2025 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.4% | +52% | $18,495,988 | +$6,069,154 | 5,067,394 | +49% | SUVRETTA CAPITAL MANAGEMENT, LLC | 31 Mar 2025 |
| Nantahala Capital Management, LLC | 7.7% | $17,439,379 | 4,777,912 | Nantahala Capital Management, LLC | 30 Sep 2024 | |||
| BlackRock, Inc. | 6% | -19% | $30,090,560 | -$7,016,336 | 3,270,322 | -19% | BlackRock, Inc. | 30 Sep 2025 |
| Adage Capital Management, L.P. | 4.5% | -44% | $22,374,400 | -$19,844,400 | 2,432,000 | -47% | Adage Capital Management, L.P. | 30 Sep 2025 |
As of 31 Dec 2025, 172 institutional investors reported holding 67,444,422 shares of Fulcrum Therapeutics, Inc. - Common Stock (FULC). This represents 100% of the company’s total 67,171,444 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Fulcrum Therapeutics, Inc. - Common Stock (FULC) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.8% | 6,561,111 | +22% | 1.8% | $74,206,165 |
| RA CAPITAL MANAGEMENT, L.P. | 9% | 6,053,960 | -41% | 0.7% | $68,470,288 |
| TCG Crossover Management, LLC | 7.8% | 5,250,000 | 0% | 2% | $59,377,500 |
| Nantahala Capital Management, LLC | 6.4% | 4,293,346 | -8.1% | 2.9% | $48,557,743 |
| BlackRock, Inc. | 6.3% | 4,263,761 | +15% | 0% | $48,223,137 |
| VANGUARD GROUP INC | 5.3% | 3,559,552 | +19% | 0% | $40,258,533 |
| BRAIDWELL LP | 4.6% | 3,061,222 | +1295% | 1.1% | $34,622,421 |
| Point72 Asset Management, L.P. | 3.6% | 2,398,232 | 0.04% | $27,124,004 | |
| Siren, L.L.C. | 2.9% | 1,950,000 | 0.66% | $22,054,500 | |
| D. E. Shaw & Co., Inc. | 2.8% | 1,913,755 | +32% | 0.02% | $21,644,569 |
| First Turn Management, LLC | 2.8% | 1,892,683 | 2.4% | $21,406,245 | |
| GSK plc | 2.7% | 1,785,714 | 0% | 2.5% | $20,196,425 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.5% | 1,700,000 | -30% | 0.03% | $19,227,000 |
| Ikarian Capital, LLC | 2% | 1,375,472 | +6.7% | 2% | $15,556,588 |
| Aberdeen Group plc | 1.9% | 1,254,027 | +809% | 0.02% | $14,183,045 |
| ADAR1 Capital Management, LLC | 1.9% | 1,253,749 | +267% | 1.1% | $14,179,901 |
| CITADEL ADVISORS LLC | 1.8% | 1,207,004 | +41% | 0.01% | $13,651,216 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 1,105,813 | +10% | 0% | $12,509,702 |
| DIMENSIONAL FUND ADVISORS LP | 1.6% | 1,051,124 | -19% | 0% | $11,888,372 |
| STATE STREET CORP | 1.5% | 1,005,345 | -5.4% | 0% | $11,370,452 |
| Balyasny Asset Management L.P. | 1.4% | 970,439 | -33% | 0.02% | $10,975,665 |
| Vestal Point Capital, LP | 1.4% | 950,000 | 0.39% | $10,744,500 | |
| GREAT POINT PARTNERS LLC | 1.2% | 800,000 | 2.9% | $9,048,000 | |
| ACADIAN ASSET MANAGEMENT LLC | 1.1% | 736,740 | +36% | 0.01% | $8,326,000 |
| Connor, Clark & Lunn Investment Management Ltd. | 0.87% | 582,377 | +52% | 0.02% | $6,586,684 |
Institutional Holders of Fulcrum Therapeutics, Inc. - Common Stock (FULC) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 17,754,084 | $136,118,842 | +$18,113,177 | $7.67 | 77 |
| 2025 Q4 | 67,444,422 | $762,744,178 | +$134,984,797 | $11.31 | 172 |
| 2025 Q3 | 53,790,538 | $494,909,349 | -$1,273,053 | $9.20 | 127 |
| 2025 Q2 | 54,400,644 | $374,498,177 | +$23,533,452 | $6.88 | 122 |
| 2025 Q1 | 51,307,184 | $147,764,693 | -$3,070,431 | $2.88 | 115 |
| 2024 Q4 | 51,666,381 | $242,831,448 | -$8,308,464 | $4.70 | 117 |
| 2024 Q3 | 54,857,560 | $195,845,950 | -$86,380,213 | $3.57 | 127 |
| 2024 Q2 | 64,752,304 | $401,470,762 | +$19,716,085 | $6.20 | 120 |
| 2024 Q1 | 60,342,845 | $569,639,654 | -$2,974,963 | $9.44 | 122 |
| 2023 Q4 | 61,083,723 | $412,326,970 | +$14,153,071 | $6.75 | 100 |
| 2023 Q3 | 56,394,454 | $250,394,156 | +$9,019,379 | $4.44 | 79 |
| 2023 Q2 | 55,518,138 | $183,197,485 | -$14,257,183 | $3.30 | 85 |
| 2023 Q1 | 60,413,854 | $172,155,022 | +$51,602 | $2.85 | 115 |
| 2022 Q4 | 50,644,890 | $368,693,025 | -$13,010,376 | $7.28 | 109 |
| 2022 Q3 | 52,209,184 | $422,360,458 | +$98,764,326 | $8.09 | 104 |
| 2022 Q2 | 40,127,745 | $196,621,873 | -$32,729,118 | $4.90 | 97 |
| 2022 Q1 | 39,071,704 | $923,864,555 | +$64,674,079 | $23.65 | 104 |
| 2021 Q4 | 37,197,291 | $657,236,909 | -$42,835,792 | $17.69 | 107 |
| 2021 Q3 | 36,552,286 | $1,031,536,477 | +$305,128,643 | $28.21 | 100 |
| 2021 Q2 | 26,798,436 | $280,833,000 | -$3,275,840 | $10.48 | 66 |
| 2021 Q1 | 26,913,060 | $317,031,000 | +$45,552,581 | $11.78 | 68 |
| 2020 Q4 | 22,170,825 | $259,615,000 | +$20,231,071 | $11.71 | 65 |
| 2020 Q3 | 20,593,739 | $163,306,000 | -$36,882,837 | $7.93 | 53 |
| 2020 Q2 | 20,455,938 | $373,550,782 | +$66,390,720 | $18.29 | 60 |
| 2020 Q1 | 16,827,383 | $200,921,119 | +$11,941,010 | $11.94 | 46 |
| 2019 Q4 | 15,784,835 | $262,061,000 | +$1,373,802 | $16.64 | 38 |
| 2019 Q3 | 15,905,791 | $105,135,052 | +$105,135,052 | $6.64 | 39 |